Pre-made Remtolumab biosimilar ( Bispecific Dual Variable Domain IG, anti-IL17A;TNFA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-478
Anti-IL17A;TNFA therapeutic antibody (Pre-made Remtolumab biosimilar,Bispecific Dual Variable Domain IG) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Remtolumab (ABT 122) is a dual-variable domain immunoglobulin, targeting tumour necrosis factor (TNF) and interleukin-17 (IL-17), that was being developed by AbbVie, for the treatment of rheumatoid arthritis and psoriatic arthritis.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL17A;TNFA therapeutic antibody (Pre-made Remtolumab biosimilar,Bispecific Dual Variable Domain IG)|
|Format||Bispecific Dual Variable Domain IG|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||4nyl:EF:AB:HL:CD/6cr1:HL;None|
|99% SI Structure||3wd5:HL;None|
|95-98% SI Structure||None;None|
|Conditions Discontinued||Psoriatic arthritis;Rheumatoid arthritis|
|Development Tech||Dual Variable Domain Immunoglobulin Technology|